Worth reading
65In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
1380000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of stock acquisition rights with an exercise price adjustment clause
Who receives how much1,380,000Shares
New shares: 1,380,000 shares during the month under review
EVO FUND (issued on 10 November 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to exercise restrictions: 6.2% (①/②)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise price in April 2026: ¥150–¥168. Details of the adjustment provisions and floor: Not disclosed
Number of Stock Acquisition Rights
Total issued: 100,000 rights; exercised during the month under review: 13,800 rights; unexercised at month-end: 59,000 rights
Procedures under the Corporate Code of Conduct
Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restrictions during the month under review was 6.2%.
Most recent equity financing
Timing Announced on 24 October 2025 and issued on 10 November 2025 / Type New shares issued through a third-party allotment, the 2025 Series 1 Stock Acquisition Rights (fixed exercise price), and the 2025 Series 2 Stock Acquisition Rights (with exercise price adjustment provisions) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of stock acquisition rights with an exercise price adjustment clause |
| Number of shares to be issued or disposed of | New shares: 1,380,000 shares during the month under review |
| Intended allottee | EVO FUND (issued on 10 November 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 6.2% (①/②) |
| Total number of issued shares | 26,004,392 shares (as of the end of the month preceding the month under review, including 78,009 treasury shares) → Not disclosed |
| Exercise price | Exercise price in April 2026: ¥150–¥168. Details of the adjustment provisions and floor: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 100,000 rights; exercised during the month under review: 13,800 rights; unexercised at month-end: 59,000 rights |
| Procedures under the Corporate Code of Conduct | Describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. The exercise ratio subject to the exercise restrictions during the month under review was 6.2%. |
| Most recent equity financing | Timing Announced on 24 October 2025 and issued on 10 November 2025 / Type New shares issued through a third-party allotment, the 2025 Series 1 Stock Acquisition Rights (fixed exercise price), and the 2025 Series 2 Stock Acquisition Rights (with exercise price adjustment provisions) / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of these Stock Acquisition Rights in April 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.